دورية أكاديمية
أعرض في EDS

Gray matter gamma-hydroxy-butyric acid and glutamate reflect beta-amyloid burden at old age.

التفاصيل البيبلوغرافية
العنوان: Gray matter gamma-hydroxy-butyric acid and glutamate reflect beta-amyloid burden at old age.
المؤلفون: Schreiner SJ; Institute for Regenerative Medicine University of Zurich Zurich Switzerland.; Department of Psychogeriatric Medicine Psychiatric University Hospital Zurich (PUK) Zurich Switzerland.; Department of Neurology University Hospital Zurich and University of Zurich Zurich Switzerland., Van Bergen JMG; Institute for Regenerative Medicine University of Zurich Zurich Switzerland., Gietl AF; Institute for Regenerative Medicine University of Zurich Zurich Switzerland.; Department of Psychogeriatric Medicine Psychiatric University Hospital Zurich (PUK) Zurich Switzerland., Buck A; Department of Nuclear Medicine University Hospital Zurich and University of Zurich Zurich Switzerland., Hock C; Institute for Regenerative Medicine University of Zurich Zurich Switzerland.; Neurimmune Schlieren Switzerland., Pruessmann KP; Institute for Biomedical Engineering University of Zurich and ETH Zurich Zurich Switzerland., Henning A; Institute for Biomedical Engineering University of Zurich and ETH Zurich Zurich Switzerland.; High-Field MR Center Max Planck Institute for Biological Cybernetics Tübingen Germany.; Advanced Imaging Research Center University of Texas Southwestern Medical Center Dallas Texas USA., Unschuld PG; Geriatric Psychiatry Service University Hospitals of Geneva (HUG) Thônex Switzerland.; Department of Psychiatry University of Geneva (UniGE) Geneva Switzerland.
المصدر: Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2024 Apr 30; Vol. 16 (2), pp. e12587. Date of Electronic Publication: 2024 Apr 30 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101654604 Publication Model: eCollection Cited Medium: Print ISSN: 2352-8729 (Print) Linking ISSN: 23528729 NLM ISO Abbreviation: Alzheimers Dement (Amst) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2020- : [Hoboken, NJ] : Wiley on behalf of the Alzheimer's Association
Original Publication: [Amsterdam] : Elsevier B.V., [2015]-
مستخلص: Gamma-hydroxy-butyric acid (GABA) and glutamate are neurotransmitters with essential importance for cognitive processing. Here, we investigate relationships between GABA, glutamate, and brain ß-amyloid (Aß) burden before clinical manifestation of Alzheimer's disease (AD). Thirty cognitively healthy adults (age 69.9 ± 6 years) received high-resolution atlas-based 1 H-magnetic resonance spectroscopic imaging (MRSI) at ultra-high magnetic field strength of 7 Tesla for gray matter-specific assessment of GABA and glutamate. We assessed Aß burden with positron emission tomography and risk factors for AD. Higher gray matter GABA and glutamate related to higher Aß-burden ( ß  = 0.60, p  < 0.05; ß  = 0.64, p  < 0.02), with positive effect modification by apolipoprotein-E-epsilon-4-allele (APOE4) ( p  = 0.01-0.03). GABA and glutamate negatively related to longitudinal change in verbal episodic memory performance ( ß  = -0.48; p  = 0.02; ß  = -0.50; p  = 0.01). In vivo measures of GABA and glutamate reflect early AD pathology at old age, in an APOE4-dependent manner. GABA and glutamate may represent promising biomarkers and potential targets for early therapeutic intervention and prevention.
Highlights: Gray matter-specific metabolic imaging with high-resolution atlas-based MRSI at 7 Tesla.Higher GABA and glutamate relate to ß-amyloid burden, in an APOE4-dependent manner.Gray matter GABA and glutamate identify older adults with high risk of future AD.GABA and glutamate might reflect altered synaptic and neuronal activity at early AD.
Competing Interests: See COI disclosure forms. Author disclosures are available in the supporting information.
(© 2024 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
References: Nat Genet. 2022 Apr;54(4):412-436. (PMID: 35379992)
Alzheimers Dement. 2020 Sep;16(9):1312-1329. (PMID: 32543726)
Neuron. 2007 Sep 6;55(5):697-711. (PMID: 17785178)
Neuroimage. 2017 May 15;152:509-516. (PMID: 28323160)
Neurobiol Aging. 2016 Dec;48:195-203. (PMID: 27718422)
Nat Neurosci. 2016 Aug;19(8):1085-92. (PMID: 27322420)
Neuroimage. 2005 Jul 1;26(3):839-51. (PMID: 15955494)
Nat Commun. 2024 Jan 3;15(1):202. (PMID: 38172114)
Neurobiol Aging. 2011 Dec;32 Suppl 1:S58-63. (PMID: 22078174)
Neurobiol Aging. 2018 Mar;63:152-161. (PMID: 29310864)
Magn Reson Med. 2001 Sep;46(3):451-6. (PMID: 11550235)
Brain. 1982 Jun;105(Pt 2):313-30. (PMID: 7082992)
Hum Brain Mapp. 2003 Aug;19(4):224-47. (PMID: 12874777)
Ann Neurol. 2018 Apr;83(4):816-829. (PMID: 29575033)
NMR Biomed. 2020 Jan 10;:e4236. (PMID: 31922301)
Neurosci Lett. 1987 Jan 2;73(1):77-80. (PMID: 2882446)
Neurobiol Aging. 2011 May;32(5):802-10. (PMID: 19501936)
Transl Psychiatry. 2022 Jun 22;12(1):257. (PMID: 35732622)
Science. 2019 Aug 9;365(6453):559-565. (PMID: 31395777)
Science. 2002 Oct 25;298(5594):789-91. (PMID: 12399581)
NMR Biomed. 2021 May;34(5):e4275. (PMID: 32078755)
NMR Biomed. 2009 Aug;22(7):683-96. (PMID: 19259944)
NMR Biomed. 2005 Dec;18(8):570-6. (PMID: 16273508)
Nat Rev Dis Primers. 2021 May 13;7(1):33. (PMID: 33986301)
J Neurosci. 2010 Oct 13;30(41):13707-17. (PMID: 20943911)
Magn Reson Imaging. 2015 Oct;33(8):1013-8. (PMID: 26117693)
Biochim Biophys Acta. 2012 Mar;1822(3):370-9. (PMID: 22108203)
Science. 2008 Sep 19;321(5896):1686-9. (PMID: 18802001)
Adv Exp Med Biol. 2006;576:183-97; discussion 361-3. (PMID: 16802713)
J Neurochem. 2018 Sep;146(6):649-669. (PMID: 29645219)
Magn Reson Med. 2017 Jan;77(1):44-56. (PMID: 26860614)
Schweiz Arch Neurol Psychiatr (1985). 1990;141(1):21-30. (PMID: 1690447)
Alzheimers Dement. 2014 Nov;10(6):735-742.e4. (PMID: 25035155)
Magn Reson Med. 2016 Jan;75(1):15-8. (PMID: 25753153)
Lancet. 2021 Apr 24;397(10284):1577-1590. (PMID: 33667416)
Neurobiol Aging. 2019 Jan;73:211-218. (PMID: 30390554)
Magn Reson Med. 2009 Jun;61(6):1279-85. (PMID: 19319893)
Brain. 2024 Feb 07;:. (PMID: 38325331)
Neurobiol Aging. 2022 Apr;112:16-26. (PMID: 35038671)
Neuroimage. 2013 Jan 1;64:112-9. (PMID: 23000786)
NMR Biomed. 2021 May;34(5):e4484. (PMID: 33559967)
Neurobiol Aging. 2015 Apr;36(4):1619-1628. (PMID: 25702957)
Neurobiol Aging. 2015 Jan;36(1):53-9. (PMID: 25169676)
J Alzheimers Dis. 2022;87(3):1131-1141. (PMID: 35431238)
Lancet Neurol. 2021 Jan;20(1):68-80. (PMID: 33340485)
Magn Reson Med. 2003 Jan;49(1):19-28. (PMID: 12509816)
Magn Reson Med. 1999 Apr;41(4):649-56. (PMID: 10332839)
NMR Biomed. 2016 Aug;29(8):1108-16. (PMID: 27351339)
J Magn Reson Imaging. 2015 May;41(5):1326-31. (PMID: 24863149)
Magn Reson Med. 1993 Dec;30(6):672-9. (PMID: 8139448)
Ageing Res Rev. 2021 Aug;69:101372. (PMID: 34029743)
Neuroimage Rep. 2021 Dec;1(4):100059. (PMID: 36896169)
J Psychiatr Res. 1982-1983;17(1):37-49. (PMID: 7183759)
Front Aging Neurosci. 2014 Sep 09;6:240. (PMID: 25249977)
Magn Reson Med. 2015 Apr;73(4):1370-80. (PMID: 24715495)
Brain. 2001 Jan;124(Pt 1):96-102. (PMID: 11133790)
Invest Radiol. 2020 Apr;55(4):239-248. (PMID: 31855587)
NMR Biomed. 2012 Jun;25(6):873-82. (PMID: 22190245)
Trends Cogn Sci. 2011 Nov;15(11):520-6. (PMID: 21983147)
Alzheimers Dement. 2020 Sep;16(9):1305-1311. (PMID: 30222945)
J Neuroimaging. 2017 Nov;27(6):630-636. (PMID: 28661060)
Neuroimage Clin. 2019;22:101776. (PMID: 30927605)
Ann Neurol. 2004 Mar;55(3):306-19. (PMID: 14991808)
فهرسة مساهمة: Keywords: 7 Tesla; APOE4; Alzheimer; GABA; aging; beta‐amyloid; biomarker; cognitive impairment; dementia; glutamate; magnetic resonance spectroscopic imaging; magnetic resonance spectroscopy; memory; positron emission tomography; prevention; synaptic dysfunction; synaptic metabolism
تواريخ الأحداث: Date Created: 20240501 Latest Revision: 20240502
رمز التحديث: 20240502
مُعرف محوري في PubMed: PMC11058481
DOI: 10.1002/dad2.12587
PMID: 38690510
قاعدة البيانات: MEDLINE
الوصف
تدمد:2352-8729
DOI:10.1002/dad2.12587